【Asset for Licensing】Orally bioavailable selective PARG small-molecule inhibitor

Asset: Orally bioavailable selective PARG small-molecule inhibitor
Development Stage: IND enabling stage
Indication: Multiple solid tumors
Key Asset Highlights:
（1）Exhibits high selectivity and potent inhibitory activity against PARG, a pivotal enzyme responsible for PAR chain degradation and a key regulator of DNA damage repair signaling in tumor cells.
（2）Effectively blocks PARG-mediated DNA repair processes, induces persistent DNA damage accumulation, and triggers robust synthetic lethal anti-tumor effects in DNA repair-deficient solid tumor subtypes.
（3）Demonstrates broad-spectrum anti-tumor potency across multiple preclinical solid tumor models, presenting differentiated therapeutic mechanisms distinct from conventional PARP inhibitors.
（4）Effectively overcomes common drug resistance limitations associated with existing DNA damage-targeted agents, providing an innovative therapeutic strategy for refractory solid tumors with unmet clinical needs.
（5）Possesses favorable oral pharmacokinetic characteristics and a well-defined safety window, supporting convenient oral dosing and sustainable clinical translation.
（6）Protected by a comprehensive global intellectual property portfolio, securing exclusive and stable development and commercialization rights for PARG-targeted solid tumor therapy.

If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.

Email: BD@drugtimes.cn

Thank you very much!

【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.